Savage price cuts for biotech floats

Shares of Memory Pharmaceuticals, the US biotechnology group, surged 42% in early trading on Nasdaq, after the pricing of its initial public offering was delayed for two weeks and the cut to $7 from an original range of $13-$15.

By the end of the first full day of trading on Tuesday, the price rose to $9.95, valuing the group at $50m (€41m). UBS and SG Cowen were joint bookrunners for the flotation which raised $35m through the sale of five million shares.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump